© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to December
oral sel. IDO1 dioxygenase inhibitor
100 mg QD, in I/O combo studies for cancer
acts on apo-IDO1 displacing heme co-factor
Mol. Cancer Ther., Dec. 9, 2020
BMS, Princeton, NJ / Flexus, San Carlos, CA
Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.